Basilea Pharmaceutica (XSWX:BSLN) EV-to-Revenue : 3.50 (As of Apr. 30, 2024)

View and export this data going back to 2004. Start your Free Trial

What is Basilea Pharmaceutica EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Basilea Pharmaceutica's enterprise value is CHF551.2 Mil. Basilea Pharmaceutica's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF157.6 Mil. Therefore, Basilea Pharmaceutica's EV-to-Revenue for today is 3.50.

The historical rank and industry rank for Basilea Pharmaceutica's EV-to-Revenue or its related term are showing as below:

XSWX:BSLN' s EV-to-Revenue Range Over the Past 10 Years
Min: 2.56 Med: 4.95 Max: 25.89
Current: 3.49

During the past 13 years, the highest EV-to-Revenue of Basilea Pharmaceutica was 25.89. The lowest was 2.56. And the median was 4.95.

XSWX:BSLN's EV-to-Revenue is ranked better than
68.47% of 1034 companies
in the Biotechnology industry
Industry Median: 7.775 vs XSWX:BSLN: 3.49

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-30), Basilea Pharmaceutica's stock price is CHF40.20. Basilea Pharmaceutica's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was CHF12.22. Therefore, Basilea Pharmaceutica's PS Ratio for today is 3.29.

Basilea Pharmaceutica EV-to-Revenue Historical Data

The historical data trend for Basilea Pharmaceutica's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica EV-to-Revenue Chart

Basilea Pharmaceutica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-Revenue

Get a 7-Day Free Trial

4.28

5.16

3.75

4.40

3.12

Basilea Pharmaceutica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EV-to-Revenue	Get a 7-Day Free Trial															3.75	-	4.40	-	3.12

Competitive Comparison of Basilea Pharmaceutica's EV-to-Revenue

For the Biotechnology subindustry, Basilea Pharmaceutica's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Basilea Pharmaceutica's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's EV-to-Revenue falls into.

Basilea Pharmaceutica EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Basilea Pharmaceutica's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	551.237	/	157.634
	=	3.50

Basilea Pharmaceutica's current Enterprise Value is CHF551.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was CHF157.6 Mil.

Basilea Pharmaceutica (XSWX:BSLN) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Basilea Pharmaceutica's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	40.20	/	12.219
	=	3.29

Basilea Pharmaceutica's share price for today is CHF40.20.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was CHF12.22.

Basilea Pharmaceutica EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Basilea Pharmaceutica (XSWX:BSLN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (XSWX:BSLN) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

BSLNz:UK

Address

Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058

Website

https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (XSWX:BSLN) Headlines

No Headlines